Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2022, Vol. 54 ›› Issue (6): 1234-1237. doi: 10.19723/j.issn.1671-167X.2022.06.030

Previous Articles     Next Articles

朝焰 徐,长艺 林*(),达梅 叶,培埕 吴,明辉 宋,有添 刘,琼 邓,雪艳 黄,忠晓 范,雪兰 游   

  • Received:2021-08-18 Online:2022-12-18 Published:2022-12-19
  • Contact: 长艺 林 E-mail:charmyarn@sina.com

RICH HTML

   

PDF (PC)

CLC Number: 

  • R593.2

Table 1

Demographic, clinical and laboratory data in two groups"

Items Group A Group B P value
Demographic data
  Age/years, M(Min, Max) 63 (20, 82) 50 (43, 75) 0.122
  Male 57.1% (12/21) 41.7% (5/12) 0.481
Clinical presentation
  Duration/d, M(Min, Max) 30 (2, 730) 5 (12, 75) 0.853
  Fever 23.8% (5/21) 33.3% (4/12) 0.699
  Joint swelling 75.0% (18/24) 78.6% (11/14) 1.000
  Joint heating sensation 50% (12/24) 57.1% (8/14) 0.745
  Limitation of joint motion 54.2% (13/24) 64.3% (9/14) 0.735
Laboratory findings
  WBC/mm3, M(Min, Max) 8 600 (2 400, 17 200) 7 900 (3 800, 19 600) 0.554
  ESR/(mm/h), M(Min, Max) 65.0 (1, 133) 88.5 (26, 140) 0.818
  CRP/(mg/L), M(Min, Max) 63.5 (0.8, 295.0) 20.8 (3.6, 213.0) 0.818

Figure 1

Sites of infected joint in two groups"

Table 2

Comorbidities and potential risk factors for infection in two groups"

Items Group A (n=21) Group B (n=12) P value
Glucocorticoid and immunosuppressant use, n(%) 9 (42.9) 5 (41.7) 1.000
Rheumatic and immune diseases, n(%) 7 (33.3) 4 (33.3) 0.723
Diabetes mellitus, n(%) 3 (14.3) 4 (33.3) 0.377
Solid cancer, n(%) 2 (9.5) 1 (8.3) 1.000
Intra-articular injection, n(%) 5 (23.8) 2 (16.7) 1.000
Skin disease, n(%) 3 (14.3) 2 (16.7) 1.000
Cacotrophy, n(%) 7 (33.3) 3 (25.0) 0.710
Other chronic disease, n(%) 10 (47.6) 6 (50.0) 1.000
1 Hassan AS , Rao A , Manadan AM , et al. Peripheral bacterial septic arthritis: Review of diagnosis and management[J]. J Clin Rheumatol, 2017, 23 (8): 435- 442.
doi: 10.1097/RHU.0000000000000588
2 Ross JJ . Septic arthritis of native joints[J]. Infect Dis Clin N Am, 2017, 31 (2): 203- 218.
doi: 10.1016/j.idc.2017.01.001
3 Gupta MN , Sturrock RD , Field M . Prospective comparative study of patients with culture proven and high suspicion of adult onset septic arthritis[J]. Ann Rheum Dis, 2003, 62 (4): 327- 331.
doi: 10.1136/ard.62.4.327
4 Newman JH . Review of septic arthritis throughout the antibiotic era[J]. Ann Rheum Dis, 1976, 35 (5): 198- 205.
5 Lee Y , Cho YS , Sohn YJ , et al. Clinical characteristics and causative pathogens of infective arthritis and risk factors for gram-negative bacterial infections[J]. Infect Chemother, 2020, 52 (4): 503- 515.
doi: 10.3947/ic.2020.52.4.503
6 Mathews CJ , Weston VC , Jones A , et al. Bacterial septic arthritis in adults[J]. Lancet, 2010, 375 (8): 846- 855.
7 Horowitz DL , Katzapa E . Approach to septic arthritis[J]. Am Fam Physician, 2011, 84 (6): 653- 660.
8 Lama V , Theyyunni N . Septic arthritis due to non-tuberculous mycobacterium without effusion[J]. J Am Emerg Med, 2021, 287 (43): e5- e7.
9 Eberst-Ledoux J , Tournadre A , Mathieu S , et al. Septic arthritis with negative bacteriological findings in adult native joints: A retrospective study of 74 cases[J]. Joint Bone Spine, 2012, 79 (2): 156- 159.
doi: 10.1016/j.jbspin.2011.04.019
10 Paosong S , Narongroeknawin P , Pakchotanon R , et al. Serum procalcitonin as a diagnostic aid in patients with acute bacterial septic arthritis[J]. Int J Rheum Dis, 2015, 18 (3): 353- 359.
11 Shen CJ , Wu MS , Lin KH , et al. The use of procalcitonin in the diagnosis of bone and joint infections: A systematic review and meta-analysis[J]. Eur J Clin Microbiol Infect Dis, 2013, 32 (6): 807- 814.
doi: 10.1007/s10096-012-1812-6
[1] Hui WEI, Jingfeng ZHANG, Zhongqiang YAO, Jinxia ZHAO. Clinical characteristics and relevant factors of rheumatoid arthritis patients with anemia of chronic disease [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 307-312.
[2] Jiyan CHU, Ping LI, Jing TIAN, Diyu FU, Lin GUO, Rui SUN, Yadi LI. Expression of the melanoma 2-mediated pyroptosis pathway in peripheral blood mononuclear cells of patients with idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 175-183.
[3] Yuan LIU, Guixiu SHI. Change from Sjögren syndrome to Sjögren disease [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1015-1017.
[4] Yirui LIAN, Jingxuan LIU, Liang ZHAO, Jing ZHAO, Sitian ZANG, Yuhui LI. Rheumatic disease spectrum and immunological profile of anti-PM/Scl antibodies in idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1018-1023.
[5] Tao WU, Jianzi LIN, Yafeng ZHU, Jianda MA, Peiwen JIA, Lijuan YANG, jie PAN, Yaowei ZOU, Ying YANG, Ye LU, Lie DAI. Serum inter-alpha-trypsin inhibitor heavy chain H3 is identified as a potential biomarker for myopenia in patients with rheumatoid arthritis using proteomic profiling [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1024-1031.
[6] Wenhao LIN, Yang XIE, Fangqing WANG, Shuying WANG, Xiangjun LIU, Fanlei HU, Yuan JIA. Single-cell RNA sequencing of B cells reveals molecular typing in Sjögren syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1032-1041.
[7] Zhao XIANG, Li YANG, Jing YANG. Untargeted metabolomics reveals differential serum metabolites and metabolic pathways in patients with primary Sjögren syndrome and thrombocytopenia [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1042-1050.
[8] Yayun ZHAO, Mengfan NI, Xue LI, Bei WANG, Gong CHENG, Jing HE, Yuebo JIN. Clinical efficacy and safety of rituximab in treating renal injury in primary Sjögren syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1051-1060.
[9] Jiajing PENG, Li CUI. Clinical features and prognosis of sarcoidosis with ocular lesions as the initial manifestation [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1061-1066.
[10] Yajing GAO, Zhengfang LI, Mengsi MA, Lijun WU. Role of the SII and SIRI in risk prediction, disease activity assessment, and prog-nostic evaluation of Behçet disease uveitis [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1067-1073.
[11] Xiaolin WANG, Shaoyi GUO, Dazhao CHEN, Xijie WEN, Yong HUA, Liang ZHANG, Qin ZHANG. A follow-up study on total hip arthroplasty in patients with systemic lupus erythematosus combined with osteonecrosis of femoral head [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1081-1088.
[12] Xinfeng WU, Siliang MAN, Dazhao CHEN, Yong HUA, Xijie WEN, Yingyue DING, Liang ZHANG, Xiujuan HOU. A long-term review for radiographic parameters of hips in axial spondyloarthritis patients with end-stage hip involvement: A 24-year trend analysis from a single high-volume tertiary center [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1089-1095.
[13] Jingwen LAN, Zhe CHEN, Yongjing CHENG, Like ZHAO. Clinical characteristics, efficacy and safety of antifibrotic agents in elderly patients with connective tissue disease-associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1101-1106.
[14] Yanyan LI, Xiangjun LIU, Gongming LI, Chun LI, Yuan JIA. Clinic behavior and therapeutic status of patients with antiphospholipid syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1107-1112.
[15] Chun WEI, Yue YANG, Xinju ZHAO, Xu LIU, Yuan JIA. Systemic lupus erythematosus complicated by autoimmune nodopathy: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1174-1179.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd